NTSR1 inhibition by a selective antagonist (SR48692) inhibits tumor growth in vivo and cell proliferation in vitro, thus confirming the oncogenic effects of NTS which acts in both the autocrine and paracrine ways98. Here, NTSR1 is linked to neoplasm.